Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cellular Senescence | 7 | 2025 | 110 | 3.860 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2025 | 111 | 2.410 |
Why?
|
| Tumor Microenvironment | 9 | 2024 | 152 | 2.010 |
Why?
|
| Pancreatic Neoplasms | 5 | 2025 | 339 | 1.870 |
Why?
|
| Immunologic Surveillance | 2 | 2025 | 22 | 1.570 |
Why?
|
| Prostatic Neoplasms | 6 | 2025 | 399 | 1.510 |
Why?
|
| Neoplasms | 6 | 2024 | 1350 | 1.460 |
Why?
|
| Killer Cells, Natural | 2 | 2024 | 216 | 1.380 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2025 | 67 | 1.100 |
Why?
|
| Cell Line, Tumor | 10 | 2025 | 1451 | 1.020 |
Why?
|
| Thiolester Hydrolases | 1 | 2025 | 9 | 0.980 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 658 | 0.910 |
Why?
|
| Immunotherapy | 5 | 2025 | 250 | 0.890 |
Why?
|
| Ovarian Neoplasms | 1 | 2025 | 144 | 0.890 |
Why?
|
| Cell Lineage | 1 | 2025 | 268 | 0.850 |
Why?
|
| Endothelial Cells | 1 | 2025 | 184 | 0.830 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2024 | 148 | 0.810 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2024 | 344 | 0.800 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 70 | 0.800 |
Why?
|
| Mice | 16 | 2025 | 10804 | 0.790 |
Why?
|
| Membrane Proteins | 2 | 2025 | 889 | 0.790 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2020 | 10 | 0.780 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2020 | 16 | 0.780 |
Why?
|
| Macrophages | 2 | 2025 | 1039 | 0.750 |
Why?
|
| Immunity, Innate | 2 | 2024 | 794 | 0.740 |
Why?
|
| Animals | 19 | 2025 | 20584 | 0.690 |
Why?
|
| Vascular Remodeling | 1 | 2020 | 24 | 0.670 |
Why?
|
| Cytostatic Agents | 1 | 2018 | 1 | 0.620 |
Why?
|
| Nanoparticles | 1 | 2024 | 517 | 0.590 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2018 | 10 | 0.540 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 27 | 0.490 |
Why?
|
| Indoles | 1 | 2015 | 110 | 0.480 |
Why?
|
| PTEN Phosphohydrolase | 5 | 2018 | 84 | 0.470 |
Why?
|
| Mesoderm | 1 | 2015 | 84 | 0.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 445 | 0.470 |
Why?
|
| Signal Transduction | 6 | 2025 | 3022 | 0.460 |
Why?
|
| Aging | 1 | 2020 | 740 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2025 | 520 | 0.440 |
Why?
|
| Humans | 18 | 2025 | 62682 | 0.380 |
Why?
|
| Neoplasm Metastasis | 5 | 2025 | 200 | 0.350 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 1005 | 0.340 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2018 | 216 | 0.340 |
Why?
|
| Retinoblastoma Protein | 2 | 2020 | 37 | 0.320 |
Why?
|
| Phenotype | 2 | 2024 | 1193 | 0.310 |
Why?
|
| Neoplastic Stem Cells | 3 | 2016 | 202 | 0.300 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 671 | 0.280 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 55 | 0.270 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 3387 | 0.260 |
Why?
|
| Mice, Transgenic | 4 | 2024 | 1271 | 0.250 |
Why?
|
| Disease Models, Animal | 4 | 2024 | 2174 | 0.250 |
Why?
|
| Cell Plasticity | 1 | 2025 | 18 | 0.240 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2025 | 52 | 0.230 |
Why?
|
| Tumor Escape | 1 | 2024 | 16 | 0.230 |
Why?
|
| Cell Proliferation | 4 | 2025 | 981 | 0.220 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2023 | 15 | 0.210 |
Why?
|
| Liver Cirrhosis | 1 | 2025 | 170 | 0.200 |
Why?
|
| Genetic Engineering | 1 | 2024 | 115 | 0.200 |
Why?
|
| Carcinogenesis | 1 | 2024 | 130 | 0.200 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 220 | 0.200 |
Why?
|
| Epithelial Cells | 1 | 2025 | 389 | 0.200 |
Why?
|
| Interferon Type I | 1 | 2024 | 186 | 0.200 |
Why?
|
| Mitochondria | 1 | 2025 | 366 | 0.190 |
Why?
|
| Calcium | 1 | 2025 | 571 | 0.180 |
Why?
|
| Genes, ras | 1 | 2020 | 27 | 0.170 |
Why?
|
| Gene Editing | 1 | 2024 | 310 | 0.160 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 81 | 0.160 |
Why?
|
| Pyrimidinones | 1 | 2018 | 16 | 0.150 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2018 | 54 | 0.150 |
Why?
|
| Purines | 1 | 2018 | 42 | 0.150 |
Why?
|
| Aminopyridines | 1 | 2018 | 32 | 0.150 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2018 | 2 | 0.150 |
Why?
|
| Tissue Engineering | 1 | 2020 | 142 | 0.150 |
Why?
|
| Pyridones | 1 | 2018 | 40 | 0.150 |
Why?
|
| Piperazines | 1 | 2018 | 76 | 0.150 |
Why?
|
| Benzimidazoles | 1 | 2018 | 54 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 225 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 189 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 129 | 0.150 |
Why?
|
| Pyridines | 1 | 2018 | 111 | 0.140 |
Why?
|
| Male | 7 | 2025 | 29487 | 0.140 |
Why?
|
| Lung | 1 | 2023 | 939 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 187 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 612 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 36 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 171 | 0.120 |
Why?
|
| Mice, SCID | 1 | 2015 | 519 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 202 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 544 | 0.110 |
Why?
|
| Blotting, Western | 1 | 2015 | 610 | 0.110 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 521 | 0.110 |
Why?
|
| Stem Cells | 1 | 2016 | 259 | 0.110 |
Why?
|
| Apoptosis | 1 | 2018 | 1066 | 0.100 |
Why?
|
| Immune Tolerance | 1 | 2014 | 175 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 761 | 0.100 |
Why?
|
| ras Proteins | 1 | 2012 | 77 | 0.090 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2099 | 0.090 |
Why?
|
| Mutation | 1 | 2018 | 2573 | 0.080 |
Why?
|
| Female | 2 | 2025 | 32495 | 0.080 |
Why?
|
| Snail Family Transcription Factors | 1 | 2025 | 28 | 0.060 |
Why?
|
| Calcium Channels | 1 | 2025 | 103 | 0.060 |
Why?
|
| HMGB1 Protein | 1 | 2024 | 26 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2025 | 172 | 0.060 |
Why?
|
| Interferons | 1 | 2024 | 74 | 0.050 |
Why?
|
| Quinuclidines | 1 | 2022 | 21 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2024 | 469 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 303 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 39 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2018 | 193 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 890 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 569 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 182 | 0.030 |
Why?
|
| Embryonic Stem Cells | 1 | 2016 | 160 | 0.030 |
Why?
|
| Arginase | 1 | 2014 | 6 | 0.030 |
Why?
|
| Anisoles | 1 | 2014 | 3 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2014 | 19 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2014 | 32 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 2014 | 33 | 0.030 |
Why?
|
| Epithelium | 1 | 2014 | 95 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2014 | 70 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1159 | 0.030 |
Why?
|
| Prostate | 1 | 2014 | 81 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2014 | 94 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2014 | 135 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 375 | 0.030 |
Why?
|
| Spleen | 1 | 2014 | 482 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 263 | 0.020 |
Why?
|
| CD24 Antigen | 1 | 2012 | 18 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2012 | 35 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2012 | 40 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 57 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 759 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 121 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2154 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 380 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 1138 | 0.020 |
Why?
|